Mark Redston

Brigham and Women's Hospital

Full Professor(heuristic)

Genetic factors in colorectal cancer · Pathology and Forensic Medicine

h-index65

i10-index98

Publications196

Citations18,864

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 25

Supplementary Table S1 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
Supplementary Table S3 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
Supplementary Table S6 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
Supplementary Table S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
Supplementary Figure S1 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
Supplementary Figure S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
Supplementary Table S4 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
Supplementary Table S5 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-06-17
The Unusual Suspects
New England Journal of Medicine · 2026-06-03
697 Thirty Years of IBD Pathology: Decreased Disease Activity in the Post-Biologic Era
Laboratory Investigation · 2026-03-01
Supplementary Table S3 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Supplementary Table S6 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Supplementary Figure S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Data from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Supplementary Table S5 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Supplementary Table S1 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Supplementary Table S4 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Supplementary Table S2 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Supplementary Figure S1 from Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
2026-02-04
Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors
Clinical Cancer Research · 2025-11-20

Open author page on OpenAlex →